Leprosy: Treatment and management of complications - 19/06/20

Doi : 10.1016/j.jaad.2019.10.138

Mayra B.C. Maymone, MD, DSc ^a, Samantha Venkatesh, MD ^b, Melissa Laughter, PhD ^a, Rana Abdat, MD ^c, Jeremy Hugh, MD ^a, Mara M. Dacso, MD, MS ^d,^e, P. Narasimha Rao, MD, DD, PhD ^f, Barbara M. Stryjewska, MD ^d, Cory A. Dunnick, MD ^a, Robert P. Dellavalle, MD, PhD, MSPH ^a,^⁎
^a Department of Dermatology, University of Colorado School of Medicine, Denver, Colorado
^b Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts
^c Department of Dermatology, Tufts Medical Center, Boston, Massachusetts
^d National Hansen's (Leprosy) Disease Program, Baton Rouge, Louisiana
^e University of Texas Southwestern Medical Center, Dallas, Texas
^f Special Interest Group on Leprosy, Indian Association of Dermatologists, Venereologists and Leprologists, Delhi, India

^∗Correspondence to: Robert P. Dellavalle, MD, PhD, MSPH, Department of Dermatology, University of Colorado School of Medicine, Rocky Mountain Regional Veterans Affairs Medical Center, 1700 N Wheeling St, Rm E1-342, Aurora, CO 80045.Department of DermatologyUniversity of Colorado School of MedicineRocky Mountain Regional Veterans Affairs Medical Center1700 N Wheeling StRm E1-342AuroraCO80045

Abstract

In the second article in this continuing medical education series, we review the treatment of leprosy, its immunologic reactions, and important concepts, including disease relapse and drug resistance. A fundamental understanding of the treatment options and management of neuropathic sequelae are essential to reduce disease burden and improve patients’ quality of life.

Le texte complet de cet article est disponible en PDF.

Key words : chemoprophylaxis, disease burden, disease relapse, drug resistance, Hansen's disease, immunoprophylaxis, leprosy, leprosy treatment, Lucio phenomenon, National Hansen's Disease Program, prevention, type 1 leprosy reaction, type 2 leprosy reaction

Abbreviations used : BB, BCG, BL, BT, ENL, LL, MB, NHDP, PB, T1R, T2R, TT, WHO